ClinicalTrials.gg

Program

piflufolastat

Also written as “piflufolastat (18F)”, “piflufolastat F 18” and “Piflufolastat F 18 Intravenous Solution [PYLARIFY]”.

Its studies are mostly in Prostatic Neoplasms · Carcinoma, Renal Cell, led by 2 companies.

Furthest: phase 4, since Oct 3, 20235 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lantheus41 open or runningphase 4since Oct 3, 2023Nov 22, 2016none ahead
Bracco10 open or runningphase 4since Sep 17, 2024Sep 17, 2024none ahead

Also a collaborator on its studies: aixial-group.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 22, 2016First study: phase 3 study in Prostatic NeoplasmsNew to LantheusLantheus · NCT02981368 · 385 enrolled · United States, Canada
  2. Nov 9, 2018Phase 3 study in Prostatic NeoplasmsLantheus · NCT03739684 · 208 enrolled · United States, Canada
  3. Oct 3, 2023Phase 4 study in Prostatic NeoplasmsLantheus · NCT06074510 · 274 enrolled · United States
  4. Sep 17, 2024Bracco's first study: phase 4 study in Prostatic NeoplasmsNew to BraccoBracco · NCT06604442 · 62 enrolled · United States
  5. May 30, 2025Phase 3 study in Carcinoma, Renal CellLantheus · NCT07084909 · United States

TargetBeta

FOLH1 →read by rule
“A urea-based radiotracer composed of the prostate specific membrane antigen (PSMA) targeting agent DCFPyL and ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07084909Carcinoma, Renal Cell · United States3WithdrawnLantheusSep 20270
NCT06604442Prostatic Neoplasms · United States4CompletedBraccoAug 29, 202562
NCT06074510Prostatic Neoplasms · United States4Active, not recruitingLantheusSep 2026274
NCT03739684Prostatic Neoplasms · United States, Canada3CompletedLantheusAug 29, 2019208
NCT02981368Prostatic Neoplasms · United States, Canada3CompletedLantheusJul 2018385

How it is read

Names in the registry

  • “piflufolastat (18F)”, 1 entry
  • “piflufolastat F 18”, 1 entry
  • “Piflufolastat F 18 Intravenous Solution [PYLARIFY]”, 1 entry
  • “18F-DCFPyL Injection”, 1 entry
  • “18F-DCFPyL”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.